Figure 1From: Investigation of novel autoantibodies in Sjogren’s syndrome utilizing Sera from the Sjogren’s international collaborative clinical alliance cohortSera were obtained from SICCA on patients with complaints of dry eyes and dry mouth who had lip biopsies with focus scores = 0 (9 patients; 4 male, mean age 49.8 years), focus scores < 1 / 4 mm2(40 patients; 3 male; mean age 49.9 years) or focus scores > 3 / 4 mm2(40 patients; 2 males; mean age 51 years). Normal controls contained 5 males and had a mean age of 37.5 years (50 patients). In the anti-CA6 studies, positives ranged from 20.7 – 46.4 and negatives from 0 – 19.6. In the anti-PSP studies, positives ranged from 20.3 – 99 and negatives from .1 – 14.6. In the anti-SP1 studies, positives ranged from 20.7 – 65.1 and negatives from 0 – 17.1. In the anti-Ro studies, positives ranged from 26.2 – 330 and negatives from 1.1 – 16.6. In the anti-La studies, positives ranged from 20.9 – 195. 4 and negatives from 0.9 – 19.6. In each of the study groups, F = 0, F <1 and F > 3, the expression of the autoantibodies, anti-CA6, anti-PSP, anti-SP1, anti-Ro and anti-La, was statistically significant when compared to the normal controls (in all cases p < .0005). The increased expression of anti- CA6 in the F0 group compared to the F <1 group (p = .032) or the F > 3 group (p = .006) were statistically significant. Neither anti-PSP nor anti-SP1 reached statistical significance because of the small numbers in the F0 group, although there was a trend for their expression to be higher in the F0 group. On the other hand, the expression of anti-Ro was significantly reduced in the F0 group compared to the F <1 (p = .0021) and F > 3 (p = .0003) groups. The reduced expression of anti-La in the F0 group compared to the F <1 and F > 3 groups did not quite reach statistical significance.Back to article page